About-cancer/treatment/drugs/caplacizumab-yhdp/zh

卡帕珠單抗

本頁包含有關caplacizumab-yhdp的簡要信息，以及一些連結，這些連結指向有關該藥物的用途，研究結果和正在進行的臨床試驗的更多信息。

美國品牌名稱

卡布利維

FDA批准

是

該藥物的FDA標籤信息可從DailyMed獲得。

用於癌症

Caplacizumab-yhdp被批准用於治療：

• 獲得性血栓性血小板減少性紫癜 （aTTP）在成人中。 它與血漿置換和免疫抑制療法一起使用。

More About Caplacizumab-yhdp

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Caplacizumab-yhdp - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.